Multiple Sclerosis: Is There a Risk of Worsening after Yellow Fever Vaccination?

Creators: Papeix, Caroline; Mazoyer, Julie; Maillart, Elisabeth; Bensa, Caroline; Dubessy, Anne-Laure; Goujon, Catherine; Launay, Odile; Lebrun-Frénay, Christine; Louapre, Céline; Mrejen, Serge; Pourcher, Valérie; Rosenheim, Michel; Stankoff, Bruno; Vidal, Jean-Sébastien; Lubetzki, Catherine

Others:: Service de Neurologie [CHU Pitié-Salpêtrière] ; IFR70-CHU Pitié-Salpêtrière [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Service de Neurologie [CHU Saint-Antoine] ; CHU Saint-Antoine [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); CIC Cochin Pasteur (CIC 1417) ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); Université Côte d'Azur (UCA); Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière] ; CHU Pitié-Salpêtrière [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU); Maladie d'Alzheimer : marqueurs génétiques et vasculaires, neuropsychologies (URP_4468) ; Groupe hospitalier Broca-Université Paris Cité (UPCité)

Description

Background: Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses. Objective: To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV. Methods: Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS. Results: 128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) ( p\,= 0.92). Time to first relapse was not different between groups (adjusted hazard ratio (HR) = 1.33; 95% confidence interval (CI) = 0.53\textendash 3.30, p = 0.54). Conclusion: These results suggest that YFV does not worsen the course of RR-MS.

Multiple Sclerosis: Is There a Risk of Worsening after Yellow Fever Vaccination?

Description

Additional details